EMBARC-RF, NCT01200992 / 2011-003496-11: Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer |
|
|
| Terminated | 3 | 84 | US, Canada, Europe | EN3348, Mitomycin C | Bioniche Life Sciences Inc. | Bladder Neoplasm, Neoplasm Recurrence, Local, Transitional Cell, Carcinoma, Carcinoma in Situ, Mycobacterium | 04/13 | 12/13 | | |
